Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ONXEO. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Key catalyst approaching
23 Aug 16
With its H116 results, Onxeo reported that R&D is progressing according to plan. Preliminary data from the Phase III ReLive trial with Livatag are due around mid-2017, which is the main catalyst in the next 12 months. Update on the newly acquired DNA repair asset, AsiDNA, revealed that the project could enter the clinic already next year. Although sales of Onxeo’s third product Beleodaq somewhat lagged our expectations, H116 operating costs were managed well, suggesting that the key catalysts are achievable with current cash.
Acquisition expands clinical pipeline
02 Jun 16
With its acquisition of DNA Therapeutics, Onxeo has added a clinical stage signal-interfering DNA (siDNA) technology, which has already been tested in a Phase I trial for melanoma and demonstrated an attractive safety profile and preliminary anti-tumour activity, when administered locally. The new product called AsiDNA is a first-in-class and differentiated asset in the up-and-coming DNA repair interference field. Our increased valuation of Onxeo is €343m.
BelCHOP data at ASH ahead of Phase III start
22 Dec 15
With Phase I data confirming the existing safety profile from the BelCHOP (Beleodaq with CHOP) study in the treatment of frontline PTCL, the path is now clear for initiation of the planned Phase III trial during H116 with partner Spectrum. Beleodaq is one of a trio of orphan oncology assets under development at Onxeo, also including Livatag (liver cancer), which has now completed seven safety reviews, and Validive (oral mucositis arising from chemoradiotherapy). New preclinical collaborations for Livatag and Beleodaq could further expand the potential of both.
LA VIE est BELle (LivAtag, ValidIvE, BELeodaq)
08 Sep 15
The next major value inflection point for Onxeo will likely be availability of Phase III Livatag data for second-line liver cancer expected H117. This product could potentially be the first launched by Onxeo in Europe as part of the orphan oncology strategy. Prior to Livatag data, progression with Beleodaq and Validive is expected, with the start of further Phase III trials anticipated in H116. Our valuation, which is largely unchanged at €328m, suggests the current share price is ascribing limited value to these assets.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
Continuing to execute strategy on core focus
03 Oct 16
Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.